Deliver Your News to the World

CybeRelease: (OTC PK: PSVI) Has Answer to Citrus Disease


(CybeRelease, December 18, 2006) - Lake Harmony, PA - Preservation Sciences, Inc. (OTC PK: PSVI), discovering new technologies through natural resources, announced today that an independent scientific study has demonstrated that its agricultural antimicrobial product Canker Kill(TM) successfully killed virtually all of the bacteria that causes citrus canker, a devastating tree disease responsible for billions of dollars in damages to the world’s orange juice and citrus trees, among other important crops.

The U.S. Department of Agriculture recently granted technical clearance for experimental use of Canker Kill in treatment of citrus canker. An independent lab, ABC Research in Gainesville, Florida, conducted controlled multi-lab tests of Canker Kill(TM), generating new data demonstrating the effectiveness of the Preservation Sciences antimicrobial product.

The experiments showed near-total suppression of the Xanthomonas bacteria, which is responsible for the citrus canker that has caused billions of dollars in damages to the nation’s citrus crops. In the tests, Preservation Science’s patent-pending Canker Kill(TM) product was effective at killing 99.995 percent of the canker bacteria, with a 98.84 percent reduction of mean canker counts following a five-minute exposure time.

To read the complete release, go to

For a Free Newsletter, go to

CybeRelease Gainers are Anglo American plc (Nasdaq: AAUK), Varian Semiconductor Equipment Associates, Inc. (Nasdaq: VSEA), Great Wolf Resorts, Inc. (Nasdaq: WOLF), Mercantile Bankshares Corporation (Nasdaq: MRBK), Umpqua Holdings Corporation (Nasdaq: UMPQ), Equinix, Inc. (Nasdaq: EQIX), Interactive Intelligence, Inc. (Nasdaq: ININ) and Sigma-Aldrich Corporation (Nasdaq: SIAL).

CybeRelease Decliners are LeCroy Corporation (Nasdaq: LCRY), deltathree Inc. (Nasdaq: DDDC), First Albany Companies, Inc. (Nasdaq: FACT), ACE*COMM Corporation (Nasdaq: ACEC), MDI, Inc. (Nasdaq: MDII), Millennium Cell Inc. (Nasdaq: MCEL), Regent Communications, Inc. (Nasdaq: RGCI) and Urologix, Inc. (Nasdaq: ULGX).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid CybeRelease $500.00 for the publication of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation, do no trading of any kind and send No Faxes or Emails.


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.